Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

SLC6A8 inhibitor

DRUG CLASS:

SLC6A8 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	RGX-202 Sensitive: C3 – Early Trials RGX-202 Sensitive : C3	RGX-202 Sensitive: C3 – Early Trials RGX-202 Sensitive : C3
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	RGX-202 Sensitive: C3 – Early Trials RGX-202 Sensitive : C3	RGX-202 Sensitive: C3 – Early Trials RGX-202 Sensitive : C3
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	RGX-202 Sensitive: C3 – Early Trials RGX-202 Sensitive : C3	RGX-202 Sensitive: C3 – Early Trials RGX-202 Sensitive : C3
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	bevacizumab + RGX-202 Sensitive: C3 – Early Trials bevacizumab + RGX-202 Sensitive : C3	bevacizumab + RGX-202 Sensitive: C3 – Early Trials bevacizumab + RGX-202 Sensitive : C3
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	bevacizumab + RGX-202 Sensitive: C3 – Early Trials bevacizumab + RGX-202 Sensitive : C3	bevacizumab + RGX-202 Sensitive: C3 – Early Trials bevacizumab + RGX-202 Sensitive : C3